このエントリーをはてなブックマークに追加
ID 48855
FullText URL
Author
Huang, P
Chen, J
Kashiwakura, Y
Saika, T
Urata, Y
Fujiwara, T ORCID Kakenhi
Abstract
OBP-301 (a telomerase-specific, replication-competent adenovirus with hTERT promoter) was constructed in a previous study and it showed a strong anticancer effect by inducing cell lysis in human lung and prostate cancer cells. This study investigated the effectiveness of a combination therapy of OBP-301 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). The cell-killing effect of OBP-301 was confirmed in vitro in the RENCA cancer cells. In in vivo experiment, luciferase-expressing RENCA cells were implanted in the left kidney and lung of BALB/c mice to prepare the RCC metastatic model. The animals were randomly divided into four treatment groups: PBS, IL-2 alone, OBP-301 alone and the combination. The analyses of orthotopic tumor weight, lung metastasis and luciferin-stained tumor images 14 days after each treatment showed significant tumor growth inhibition in the combination group in comparison with that in the OBP-301- or IL-2-treated groups. In addition, the percentage of regulatory T-cells (Tregs) in the combination group was significantly suppressed in comparison with that in the PBS and single-agent treatment groups. The outcomes of this study suggest that tumor-specific oncolytic immunovirotherapy may become an attractive strategy for the treatment of human RCC.
Keywords
renal cell carcinoma
OBP-301
adenovirus
hTERT
interleukin-2
Published Date
2010-07
Publication Title
Cancer Gene Therapy
Volume
volume17
Issue
issue7
Publisher
Nature Publishing Group
Start Page
484
End Page
491
ISSN
0929-1903
NCID
AA12570566
Content Type
Journal Article
Project
Innovation Center Okayama for Nanobio-targeted Therapy(ICONT)
Official Url
http://www.nature.com/cgt/journal/v17/n7/full/cgt20105a.html
language
英語
Copyright Holders
© Nature Publishing Group
File Version
author
Refereed
True
DOI
PubMed ID
Web of Sience KeyUT